22 min listen
Management of Non-Small Cell Lung Cancer with ALK and ROS1 Rearrangements with Dr Ross Camidge
Management of Non-Small Cell Lung Cancer with ALK and ROS1 Rearrangements with Dr Ross Camidge
ratings:
Length:
39 minutes
Released:
Nov 18, 2020
Format:
Podcast episode
Description
Dr Ross Camidge from the University of Colorado in Denver discusses recently published and emerging research in the management of non-small cell lung cancer with ALK and ROS1 rearrangements.
CME information and select publications here (http://www.researchtopractice.com/OncologyTodayALKNSCLC20).
CME information and select publications here (http://www.researchtopractice.com/OncologyTodayALKNSCLC20).
Released:
Nov 18, 2020
Format:
Podcast episode
Titles in the series (100)
Dr Tom Lynch on Adjuvant EGFR TKIs in Lung Cancer and COVID-19 in Seattle: Dr Tom Lynch comments on the current status of oncology research and data soon to be presented from a Phase III trial evaluating the EGFR TKI osimertinib as adjuvant therapy for patients with non-small cell lung cancer and EGFR tumor mutations. by Oncology Today with Dr Neil Love